立体定向放射外科治疗嗅沟脑膜瘤:国际多中心研究
该国际多中心研究汇总了278例WHO I级嗅沟脑膜瘤患者,接受立体定向放射外科(SRS)后中位影像随访39个月,43%部分或边缘缓解、54%稳定、3%进展。中位临床随访51个月,13%出现临床和/或影像学不良放射事件(ARE),较大肿瘤体积和SRS前瘤周T2/FLAIR信号异常与ARE风险升高相关。SRS后90%患者嗅觉稳定、8%改善、2%恶化。
要点
- SRS对多数WHO I级嗅沟脑膜瘤可获得持久局部控制,安全性可接受。
- 较大肿瘤体积和SRS前瘤周T2/FLAIR信号异常与不良放射事件风险升高相关。
- SRS后多数患者嗅觉稳定或改善,SRS前嗅觉丧失和既往手术切除预测完全嗅觉丧失。
核心结论
- SRS对多数嗅沟脑膜瘤患者可获得持久局部控制,安全性可接受。
- SRS使多数嗅沟脑膜瘤患者嗅觉功能得以保留或改善。
研究设计与样本
- 国际放射外科研究基金会20家机构参与的多中心研究, pooled分析278例组织学确诊或影像学怀疑的WHO I级嗅沟脑膜瘤患者,SRS后随访至少6个月。
- 患者中位年龄57岁,组织学确诊占29%,影像学怀疑占71%。
主要发现
- 中位治疗体积4.60 cm3(范围0.12-27.3 cm3),中位处方剂量12 Gy,中位嗅神经剂量11.20 Gy。
- 中位影像随访39个月(范围6-240个月),43%部分或边缘缓解,54%稳定,3%进展。
- 中位临床随访51个月(范围6-240个月),36例(13%)出现临床和/或影像学不良放射事件(ARE)。
- 较大肿瘤体积(P = .009)和SRS前瘤周T2/FLAIR信号异常(P < .001)与ARE风险升高相关。
- SRS后嗅觉稳定、改善、恶化分别占90%、8%、2%;完全嗅觉丧失由SRS前部分/完全嗅觉丧失(OR = 83.125;95% CI [24.589-281.01],P < .001)和既往嗅沟脑膜瘤切除(OR = 3.919;95% CI [1.713-8.970],P = .001)预测。
临床怎么用
- 对于选择的WHO I级嗅沟脑膜瘤患者,SRS是可考虑的治疗方式,可实现持久局部控制并保留或改善嗅觉。
- 治疗前应评估肿瘤体积和瘤周T2/FLAIR信号异常,以识别ARE风险较高的患者。
- 治疗前存在嗅觉丧失或既往手术切除的患者,SRS后完全嗅觉丧失风险较高,应予以告知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic radiosurgery (SRS) is increasingly considered for selected olfactory groove meningiomas (OGMs). OBJECTIVE: To investigate the safety and efficacy of SRS for OGMs. METHODS: From 20 institutions participating in the International Radiosurgery Research Foundation, we pooled patients who underwent SRS for histologically confirmed or radiologically suspected WHO grade I OGMs and were followed for 6 mo or more after the SRS. RESULTS: In total, 278 (median age 57 yr) patients underwent SRS for histologically confirmed (29%) or radiologically suspected (71%) WHO grade I OGMs Median treatment volume was 4.60 cm3 (range: 0.12-27.3 cm3), median prescription dose was 12 Gy, and median dose to the olfactory nerve was 11.20 Gy. During median post-SRS imaging follow-up of 39 mo (range: 6-240 mo), 43% of patients had partial or marginal response, 54% of patients had stable disease, and 3% of patients experienced progression. During median post-SRS clinical follow-up of 51 mo (range: 6-240 mo), 36 (13%) patients experienced clinical and/or radiological adverse radiation events (AREs). Elevated risk of AREs was associated with larger OGM volume (P = .009) and pre-SRS peritumoral T2/fluid-attenuated inversion-recovery signal abnormalities (P < .001). After the SRS, olfaction remained stable, improved, or deteriorated in 90%, 8%, and 2% of patients, respectively. Complete post-SRS anosmia was predicted by partial/complete anosmia before the SRS (odds ratio [OR] = 83.125; 95% CI [24.589-281.01], P < .001) and prior resection of OGM (OR = 3.919; 95% CI [1.713-8.970], P = .001). CONCLUSION: SRS is associated with durable local control of the majority of OGM patients with acceptable safety profile. SRS allows preservation or improvement of olfactory function in the majority of OGM patients.
引用
- Bunevicius A, Ahn J, Fribance S, et al. Stereotactic Radiosurgery for Olfactory Groove Meningiomas: An International, Multicenter Study. Neurosurgery. 2021. PMID: 34383951. doi:10.1093/neuros/nyab291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。